PHARMA NEWS, MULTICHANNEL & CROSSCHANNEL MAKETING
311.3K views | +5 today
Follow

Biggest influencers in digital pharma in Q2 2020: The top individuals to follow #pharma #hcsmeufr #esante

From www.pharmaceutical-technology.com

GlobalData research has found the top digital pharma influencers based on their performance and engagement online in Q2 2020.

Lionel Reichardt / le Pharmageek:

Biggest influencers in digital pharma in Q2 2020: The top individuals to follow #pharma #hcsmeufr #esante

GlobalData research has found the top digital pharma influencers based on their performance and engagement online in Q2 2020.

No comment yet.

Lancement de Coalition Next pour favoriser l'innovation en santé

From buzz-esante.fr

Emanation de la Coalition Innovation Santé – Crise sanitaire lancée en 2020, Coalition Next…
No comment yet.

Digital Transformation in Life Sciences | Deloitte US

From www2.deloitte.com

Digital transformation is no longer a buzzword—it’s a strategic imperative. How can life sciences companies advance their capabilities and take a more holistic view of their digital strategies?
No comment yet.

Facts for thoughts #esante #hcsmeufr #digitalhealth #pharma

From www.across.health

Facts for thoughts: shared insights to inspire biopharma thinking and reimagine customer engagement.
No comment yet.

The acceleration of pharma’s digital transformation #esante #hcsmeufr #digitalhealth

From dominictyer.wordpress.com

Pharmaceutical sales, marketing, and research and development have followed a steep learning curve during the COVID-19 pandemic that has sped up use of digital health and other tech
No comment yet.

Eli Lilly, Welldoc collaborate on new version of BlueStar platform #esante #hcsmeufr #digitalhealth

From www.mobihealthnews.com

The pair will work on integrating Welldoc's software into Lilly's not yet released insulin pen.
No comment yet.

Ipsen forms digital health partnership to boost rare disease diagnosis #esante #hcsmeufr #digitalhealth

From www.epmmagazine.com

Ipsen Pharmaceuticals and rare disease digital health specialists, Mendelian, has launched a new partnership to utilise Mendelian’s MendelScan software, a Class 1 Medical Device capable of aiding the rapid identification of people with rare diseases.
No comment yet.

UCB taps Microsoft to accelerate drug discovery, clinical trials #esante #hcsmeufr #digitalhealth

From www.fiercebiotech.com

UCB and Microsoft have entered into a multiyear strategic collaboration. The deal will see Microsoft use its capabilities in computational services, cloud computing and artificial intelligence to support drug discovery and development at UCB.
No comment yet.

Otsuka, Click Therapeutics kick off decentralized pivotal trial for depression digital therapeutics #esante #hcsmeufr #digitalhealth

From www.mobihealthnews.com

The randomized controlled trial of the jointly-developed digital therapeutics will be conducted using Verily's Project Baseline and enroll up to 540 patients.
No comment yet.

Innovation in Diabetes Care Technology: Value-based Agreements - IQVIA

From www.iqvia.com

About the Report


The increasing use of digital technologies for diabetes indicates the health system has entered a new era of diabetes care. Increased digitalization, and particularly the use of digital medicine products such as connected devices and digital applications, offers many potential benefits such as improved health outcomes, increased care efficiency, and improved quality of life for people with diabetes. However, in order for the value of these tools to be realized, health policy and healthcare practice must continue to modernize to allow for improved patient access and use. In the area of reimbursement, value-based agreements (VBAs) show promise as one way to realize the value of digital medicine product innovations while also generating further evidence for the healthcare system.

Report Summary


Within the U.S. healthcare system, the prevalence of chronic conditions such as diabetes is increasing, as are diabetes care expenditures. In order to improve health outcomes associated with diabetes and to better manage care expenses, novel reimbursement mechanisms such as VBAs can help improve access to and use of new innovations. In its most simple form, value-based healthcare focuses on improving care outcomes and value realized from care expenditures. Operationally, VBAs can act to align health system stakeholder interests, ideally improving health outcomes and reducing care costs in the target patient population. 



VBAs between manufacturers and payers can largely be categorized as either performance-based or differential pricing-based VBAs. The former links payment to the demonstrated patient outcomes, while in the latter, pricing varies based on the clinical value relative to existing treatments. In both cases, incentives are greater for products that work and less for those that do not. VBAs are gaining some traction and use in the U.S. healthcare system, but they can be more complex to implement than traditional rebate or discount agreements. Challenges can include defining which outcomes to measure, aligning on agreement terms, tracking performance, overcoming insufficient data infrastructure, and navigating potential regulatory concerns. To allow for more widespread uptake and adoption of VBAs, educational opportunities to learn about VBAs, the establishment of basic frameworks, federal policies, and efforts to appropriately share real-world experience with VBAs and their impact will all be helpful. 
No comment yet.

TecHopital - Les 10 premières start-up lauréates du programme Inno Vaccins #innovaccins

From www.techopital.com

TecHopital.com est un site dédié aux cadres techniques et ingénieurs hospitaliers. Il traite d'actualités pratiques, de retours sur expérience et des nouvelles initiatives dans l'ingénierie, l'architecture, les fonctions supports, les équipements biomédicaux, ou tout autre domaine à caractère technique et scientifique permettant le fonctionnement des établissements de santé.
No comment yet.

Innovation in Diabetes Care Technology: The User Experience - IQVIA  #esante #hcsmeufr #digitalhealth

From www.iqvia.com

About the Report


Throughout the eras of diabetes care, there has been a trend to advance care tools, approaches, and measures to aid people with diabetes (PwD) and healthcare professionals in their efforts to optimally manage the disease. This is because effective daily management of diabetes has important implications for PwD health outcomes and the healthcare system and poses a significant care burden for insulin using PwD. Uptake of digital medicine products that offer to improve disease burden is increasing, but these are still not widely adopted in diabetes care. Maximizing the value that can be derived from these new digital tools requires an improved understanding of their impact on quality of life and day-to-day experiences for PwD. Such factors are crucial in supporting PwD initiation, optimization, and sustained use of digital medicine products. 



Report Summary


Recent advances in the diabetes care paradigm have brought us into a new era of care. Among these are digital medicine products, including continuous glucose monitors, connected insulin pens, and advanced hybrid closed-loop insulin pumps, as well as the monitoring of diabetes outcome metrics such as HbA1c and, increasingly, time-in-range (TIR, which can be defined as the percentage of time a PwD spends in their glucose target range). However, despite these advances, significant care gaps persist and demonstrate a need for improvement in blood glucose management. 



In order to realize the most value from advances in diabetes digital medicine products, health policy and practice also critically need to evolve to support PwD use of these technologies. Although early studies have demonstrated promising outcomes from integrating diabetes digital medicine products into care, the decision by PwD to initiate the use of technology and then optimize and sustain its use can be complex and is therefore deserving of attention. Given a myriad of choices, PwD must weigh various decisions in order to find a digital medicine product that is compatible with their lifestyle and care aspirations. Further, the PwD must be willing to integrate the digital medicine product into their daily routine through collaboration with payers, HCPs, and support personnel through phases to initiate, optimize, and sustain use. 



To improve access to the value embedded in this new era of care, it is critical to understand the experience of the person with diabetes in assessing, using, and benefiting from diabetes digital health products.  It may be beneficial to offer further support to PwD throughout the phases of initiation, optimization, and sustained use by providing increased access to actionable information, developing user-friendly guidelines and/or product support, and increasing overall health system integration, as a few examples. 
No comment yet.

2021 Global health care sector outlook #esante #hcsmeufr #digitalhealth

From www2.deloitte.com

This report examines the top issues impacting the global health care sector in 2020.
No comment yet.

L'investissement dans le numérique pris en compte dans la régulation du prix des médicaments #esante #hcsmeufr #digitalhealth

From www.ticpharma.com

PARIS (TICpharma) - Le nouvel accord-cadre sur le médicament signé le 5 mars entre le Comité économique des produits de santé (CEPS) et le Leem (Les entreprises du médicament) prévoit que les investissements réalisés par les industriels dans les "solutions numériques" pourront désormais être pris en compte afin que leurs produits bénéficient d'une période de stabilité de prix.
No comment yet.

2020 physician survey #esante #hcsmeufr #digitalhealth

From www2.deloitte.com

COVID-19 changed orthodoxies and pushed physicians to adopt virtual health. It’s time for health care systems to redefine conventions, consolidate the learnings, and scale up what worked to achieve a seamless patient and physician experience.
No comment yet.

Un large plébiscite pour les outils digitaux #esante #hcsmeufr #digitalhealth

From www.dsih.fr

D’après le Baromètre 360 Medics, 87 % des médecins utilisent au moins un outil digital dans leur pratique depuis la crise sanitaire contre 79 % auparavant, soit une augmentation de 8 %.
No comment yet.

Otsuka launches pivotal trial of digital therapeutics for depression #esante #hcsmeufr #digitalhealth

From medcitynews.com

Otsuka Pharmaceutical is partnering with Click Therapeutics to launch a remote clinical trial to evaluate the effectiveness of digital therapeutics in reducing depressive symptoms.
No comment yet.

Wireless skin sensors for physiological monitoring of infants in low-income and middle-income countries #esante #hcsmeufr #digitalhealth

From www.thelancet.com

Globally, neonatal mortality remains unacceptability high. Physiological monitoring
is foundational to the care of these vulnerable patients to assess neonatal cardiopulmonary
status, guide medical intervention, and determine readiness for safe discharge. However,
most existing physiological monitoring systems require multiple electrodes and sensors,
which are linked to wires tethered to wall-mounted display units, to adhere to the
skin. For neonates, these systems can cause skin injury, prevent kangaroo mother care,
and complicate basic clinical care.
No comment yet.

Roche inks deal with Diabeloop to integrate automated insulin delivery

From www.mobihealthnews.com

As part of the partnership Roche's Accu-Chek insulin pump can integrate with Diabeloop monitoring system.
No comment yet.

La connaissance client au service d'un marketing ultra-personnalisé

From www.kissthebride.fr

Découvrez comment la Data et la connaissance client vous permettent de proposer une experience personnalisé à vos clients.
No comment yet.

Connaissance client : quand les données ne suffisent plus...

From comarketing-news.fr

Malgré la multiplication des données disponibles, seules 2 entreprises sur 10 considèrent avoir un très bon niveau de connaissance client. Dans un
No comment yet.

Sensor Cloud: Pioneering the Next Generation of Virtual Trials Technology

From www.medidata.com

Reading Time: 2 minutes COVID-19 has accelerated the need for technologies that support the adoption of more flexible clinical trials, as challenges abound for traditional methods. Patient recruitment, of course, has always been one of the most significant challenges for the industry, with four out of five sites being unable to fulfill enrollment requirements. Furthermore, 30% of trials are …
No comment yet.